<DOC>
	<DOCNO>NCT02539719</DOCNO>
	<brief_summary>This Phase 1a/1b study SC-003 patient platinum-resistant/refractory ovarian cancer . SC-003 antibody-drug conjugate ( ADC ) comprise monoclonal antibody link potent chemotherapy .</brief_summary>
	<brief_title>Study SC-003 Subjects With Platinum-Resistant/Refractory Ovarian Cancer</brief_title>
	<detailed_description>Phase 1a dose escalation study patient histologically/cytologically confirm ovarian cancer platinum-resistant refractory . Phase 1b expansion study patient enrol treat recommend dose schedule base Phase 1a .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<criteria>Histologically cytologically confirm ovarian epithelial cancer Evidence progressive disease ( PD ) within 6 month platinum ( cisplatin carboplatin ) regimen : least 1 prior regimen must contain platinumtaxane combination Measurable disease define RECIST 1.1 Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Fresh archive tumor tissue sample available target expression analysis . [ Phase 1b : Subjects ' tumor tissue must test positive target expression . ] Adequate hematologic organ function confirm laboratory value At least 3 week last systemic chemotherapy plan start study treatment ( 4 week prior investigational drug biologics ) ovarian cancer At least 3 week major surgery plan start study treatment ; major incision must heal History prior malignancy , exception following : malignancy treat curative intent evidence active disease present 3 year prior screen felt low risk recurrence treat physician ; adequately treat lentigo maligna melanoma without current evidence disease adequately control nonmelanomatous skin cancer ; adequately treat cervical carcinoma situ without current evidence disease . Uncontrolled infection require systemic antibiotics/antivirals/antifungals Peripheral neuropathy â‰¥ grade 2 Radiotherapy &gt; 25 % bone marrow prior initiation therapy Evidence complete partial bowel obstruction Patients require IV hydration parenteral nutrition Positive pregnancy test female childbearing potential pregnant currently breastfeed Known hypersensitivity component study drug Inability tolerate premedication dexamethasone Uncontrolled cardiac disease , myocardial infarction within last 12 month , leave ventricular ejection fraction ( LVEF ) &lt; 50 % , QTcF interval &gt; 470 msec Class II , III IV heart failure define NYHA functional class system Positive serology hepatitis B C , know human immunodeficiency virus infection ( HIV ) Previous treatment pyrrolobenzodiazepine ( PBD ) base drug</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Platinum-Resistant</keyword>
	<keyword>Refractory</keyword>
</DOC>